Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 3/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 2/20 | 0.39 |
| ▸ | CCND1 | P24385 | 2/20 | 0.39 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2970593 | 0.91 | MPL (0.37) | MPLGBA1CDK4CCND1LMNA | |
| SCHEMBL2978158 | 0.88 | DHODH (0.46) | DHODH | |
| SCHEMBL2978816 | 0.87 | BAZ2B (0.44) | GBA1LMNAMAPTBAZ2BRBP4 | |
| SCHEMBL2986272 | 0.85 | SIRT2 (0.46) | GBA1LMNAMAPTBAZ2BSIRT2 | |
| SCHEMBL2966428 | 0.84 | SIRT2 (0.40) | DHODHLMNAMAPTBAZ2BSIRT2 | |
| SCHEMBL2981584 | 0.84 | SIRT2 (0.40) | DHODHLMNAMAPTBAZ2BSIRT2 | |
| SCHEMBL2973482 | 0.84 | SIRT2 (0.44) | GBA1CDK4CCND1LMNAMAPT | |
| SCHEMBL2970394 | 0.84 | SIRT2 (0.44) | MPLGBA1LMNAMAPTBAZ2B | |
| SCHEMBL2980535 | 0.83 | SIRT2 (0.44) | MAPTBAZ2BSIRT2CFTR | |
| SCHEMBL2978681 | 0.83 | SIRT2 (0.44) | DHODHLMNAMAPTBAZ2BSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772245-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1851219-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | Miikana Therapeutics, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060199829-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006088949-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199829-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | MPL 4770/4885GBA1 1174/4885CDK4 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.